Prospective multi-center validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced non-small cell lung cancer.

Fiche publication

Date publication

février 2021

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle

Tous les auteurs :
Ilie M, MaziÈres J, Chamorey E, Heeke S, Benzaquen J, Thamphya B, Boutros J, Tiotiu A, Fayada J, Cadranel J, Poudenx M, Moro-Sibilot D, Barlesi F, Thariat J, Clement-Duchene C, Tomasini P, Hofman V, Marquette CH, Hofman P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33545389

Résumé

Patients with advanced-stage non-small cell lung cancer (NSCLC) whose tumors harbor an anaplastic lymphoma kinase (ALK) gene rearrangement benefit from treatment with multiple ALK inhibitors (ALKi). Approximately 30% of tumor biopsies contain insufficient tissue for successful ALK molecular characterization. This study evaluated the added value of analyzing circulating tumor cells (CTCs) as a surrogate to ALK tissue analysis and as a function of the response to ALKi.